Austedo in 2026: A Provider Briefing on Access and Availability

Deutetrabenazine (Austedo, Austedo XR) remains a cornerstone therapy for tardive dyskinesia (TD) and chorea associated with Huntington's disease (HD). As a prescriber, you've likely fielded calls from patients unable to fill their Austedo prescriptions — even when there's no formal supply disruption. This article provides a comprehensive overview of the current availability landscape, prescribing considerations, and practical tools to help your patients maintain access to this medication in 2026.

Current Supply Status

As of early 2026, Austedo (Deutetrabenazine) is not listed on the FDA's drug shortage database. Teva Pharmaceuticals continues to manufacture both formulations:

• Austedo — immediate-release tablets (6 mg, 9 mg, 12 mg), dosed twice daily with food
• Austedo XR — extended-release tablets (6 mg, 12 mg, 24 mg), dosed once daily

However, the absence of a formal shortage designation does not reflect the access difficulties many patients encounter. The real barriers are structural — related to distribution, insurance, and cost — rather than manufacturing-based.

Timeline: Key Milestones

• April 2017 — FDA approves Deutetrabenazine (Austedo) for chorea associated with Huntington's disease; first deuterated drug approved
• August 2017 — FDA expands approval to include tardive dyskinesia
• 2023–2024 — Austedo XR (extended-release) formulation launched, offering once-daily dosing
• June 2025 — European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for Austedo for TD in adults
• 2026 — No generic Deutetrabenazine available; Teva remains sole manufacturer

Prescribing Implications

Dose Management and CYP2D6 Considerations

Deutetrabenazine is extensively metabolized by CYP2D6. The active metabolites (α-HTBZ and β-HTBZ) drive clinical effect. Key prescribing considerations include:

• CYP2D6 poor metabolizers: Maximum recommended dose is 36 mg/day (vs. 48 mg/day for extensive/intermediate metabolizers)
• Concomitant strong CYP2D6 inhibitors (Paroxetine, Fluoxetine, Bupropion, Quinidine): Dose adjustment may be needed; total daily dose should generally not exceed 36 mg
• Re-titration required: If a patient misses more than one week of therapy, re-titration from 6 mg/day is recommended

This re-titration requirement makes uninterrupted access critically important. Even brief lapses in supply can set patients back weeks in achieving therapeutic benefit.

Contraindications to Review

Ensure patients are not concurrently taking:

• Reserpine (must wait 20 days after discontinuation)
• MAO inhibitors (14-day washout required in either direction)
• Tetrabenazine or Valbenazine (concurrent VMAT2 inhibitor use is contraindicated)

For patients with hepatic impairment, Deutetrabenazine is contraindicated. For details on drug interactions, see Austedo drug interactions: what to avoid.

Boxed Warning: Depression and Suicidality

The boxed warning applies specifically to patients with Huntington's disease. Deutetrabenazine may increase the risk of depression and suicidal ideation in this population. Patients with untreated or inadequately treated depression should not be started on Austedo. Regular mental health monitoring is essential.

The Availability Picture

Patient access challenges stem from several structural factors:

Specialty Pharmacy Requirements

Most payers route Austedo through specialty pharmacy channels. This limits where patients can fill prescriptions and adds processing time. Patients accustomed to same-day fills at retail pharmacies may not understand why their Austedo prescription takes longer.

Prior Authorization and Step Therapy

Nearly all commercial and Medicare plans require prior authorization for Austedo. Many also impose step therapy requirements, particularly for tardive dyskinesia, where insurers may require documentation that alternative treatments were tried. Preparing thorough PA documentation upfront can reduce delays.

Cost as a Barrier

At $7,000 to $10,000 per month cash price, Austedo is prohibitively expensive for uninsured patients and creates high copay burdens even for those with insurance. Specialty tier placement means copays of $100 to $500+ per month for many commercially insured patients.

Cost and Access Support

Several programs exist to help patients afford Austedo:

• Teva Copay Savings Program: Reduces copays to as low as $0 for eligible commercially insured patients. Not available for government-funded insurance (Medicare, Medicaid, Tricare, VA)
• Teva Cares Foundation: Provides free medication to qualifying uninsured or underinsured patients. Application is through the prescriber's office or tevacares.org
• Independent copay assistance foundations: Organizations such as the HealthWell Foundation and Patient Access Network Foundation periodically offer grants for movement disorder medications

For a patient-facing resource on savings options, direct patients to how to save money on Austedo. For the provider perspective on helping patients navigate costs, see how to help patients save money on Austedo: a provider's guide.

Tools and Resources for Providers

Medfinder for Providers

Medfinder offers a provider-facing tool that allows you and your staff to check real-time pharmacy availability for Austedo. This can help you direct patients to pharmacies that currently have the medication in stock, rather than sending them on a frustrating search.

Formulary and PA Resources

Keep current PA templates and supporting documentation (AIMS scores, prior treatment history, diagnostic confirmation) readily accessible. Having these materials pre-prepared can significantly reduce the time from prescription to fill.

Peer-to-Peer Review Preparation

If a PA is denied, be prepared for peer-to-peer review with the insurer's medical director. Key talking points include:

• FDA-approved indication and clinical necessity
• AIMS score documentation (for TD patients)
• Prior treatment failures or intolerability
• Re-titration risk with treatment interruption

Looking Ahead

No generic Deutetrabenazine is expected in the near term, meaning these access and cost challenges will persist. The 2025 EMA positive opinion for Austedo in the EU may signal broader global availability but doesn't directly affect U.S. supply dynamics.

Providers should continue to:

• Initiate PA requests as early as possible during titration
• Educate patients about the re-titration requirement and the importance of uninterrupted therapy
• Connect patients with Teva's support programs and tools like Medfinder
• Stay informed about formulary changes and new copay assistance fund openings

For a practical guide on helping patients navigate the Austedo access landscape, see how to help your patients find Austedo in stock.

Final Thoughts

Austedo remains an effective and well-tolerated treatment for tardive dyskinesia and Huntington's chorea, but the path from prescription to patient is more complex than it should be. By understanding the structural barriers, leveraging available support programs, and using tools like Medfinder, providers can play a critical role in ensuring their patients maintain uninterrupted access to this important therapy.

This article is for informational purposes only and does not constitute medical advice. Clinical decisions should be made in consultation with the treating physician based on individual patient circumstances.